Safe Discontinuation of Pyridostigmine

General Considerations

Pyridostigmine should be gradually tapered rather than abruptly discontinued to prevent rebound worsening of symptoms, especially in patients with myasthenia gravis or orthostatic hypotension 1, 2
The American College of Cardiology recommends monitoring blood pressure in both supine and standing positions during the taper for orthostatic hypotension patients 5

Begin by reducing the dose by 30 mg (half a tablet) every 3-7 days while monitoring for symptom recurrence 1, 2
If symptoms worsen during tapering, return to the previous well-tolerated dose and slow the tapering schedule 3
Consider neurological consultation before initiating the taper, especially for patients with myasthenia gravis 4

Patients with more severe underlying conditions may require slower tapering schedules 1, 4
If the patient is also on corticosteroids for myasthenia gravis, do not taper both medications simultaneously 3, 4
Avoid medications that can worsen myasthenia symptoms during the tapering process (β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolides) 3, 4

Watch for signs of symptom recurrence, which may indicate the need to slow the tapering process 3, 4
For myasthenia gravis patients: monitor for increased muscle weakness, fatigue, ptosis, diplopia, or difficulty swallowing 1
Development of significant weakness, especially involving respiratory muscles, requires immediate medical attention 1, 3
Severe orthostatic symptoms with significant drops in blood pressure require immediate medical attention 5